Document is current
Any future updates will be listed below
-
Authors
Friedman, Scott M.
Xu, Yingxin
Sherman, Steven
Kuznik, Andreas
Mojebi, Ali
Keeping, Sam
Chan, Keith
Leng, Theodore
Patel, Nimesh
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 7 July 2025
Accepted: 8 September 2025
First Online: 25 September 2025
Declarations
:
: Scott Friedman has received grants or contracts from Bayer, JAEB Center, Ophthea, Regeneron Pharmaceuticals, Inc., Genentech, Amgen, Clearside Biomedical, EyePoint, ONL Therapeutics, REGENXBIO, Kowa, Kodiak Sciences, and Belite Bio, has participated on a Data Safety Monitoring Board or Advisory Board for Amgen, Genentech, and Ocular Therapeutics, and has stock or stock options in REvOpsis. Yingxin Xu, Andreas Kuznik, and Steven Sherman are employees and stockholders of Regeneron Pharmaceuticals, Inc. Ali Mojebi, Sam Keeping, and Keith Chan are employees of Precision AQ, which received funding from Regeneron Pharmaceuticals, Inc. for conducting this analysis. Theodore Leng has received funding from Astellas and served as a consultant for Astellas, Boehringer Ingelheim, Roche/Genentech, Topcon, Toku, and Virtual Field. Nimesh Patel has served as an advisor for Alcon, Alimera, Allergan, Apellis, Biogen, DORC, EyePoint, Genentech, Kyoto Drug Company, Regeneron Pharmaceuticals, Inc., and REGENXBIO.
: This NMA uses data from previously conducted clinical trials and does not report any new data from trials conducted in human participants by any of the authors.
